Skip to main content
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging 3/2010

01.03.2010 | Original Article

Time-dependent changes in 18F-FDG activity in the thymus and bone marrow following combination chemotherapy in paediatric patients with lymphoma

verfasst von: Ingeborg Goethals, Pieter Hoste, Ciel De Vriendt, Peter Smeets, Joris Verlooy, Hamphrey Ham

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 3/2010

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To investigate the time-dependent changes in 18F-FDG uptake by the thymus and marrow following combination chemotherapy for lymphoma in a paediatric study population.

Methods

Included in the study were 27 paediatric patients who were in complete metabolic remission after chemotherapy and who underwent off-therapy follow-up with serial whole-body PET-CT scans. A total of 142 PET-CT scans were recorded. 18F-FDG uptake by the thymus and marrow was assessed both visually and semiquantitatively. Visual uptake was scored on the three-dimensional maximum intensity projection of the whole-body PET image according to a three-point scale. For the semiquantitative assessment, standard uptake values were measured. To find a pattern in the 18F-FDG uptake by the thymus and marrow a moving average technique was applied.

Results

Our time series analysis indicated that the marrow activity was highest at cessation of chemotherapy and declined thereafter. During an off-chemotherapy period of on average 6 months, marrow activity decreased quickly. From 6 months onward, the activity declined more slowly. The posttherapy changes in 18F-FDG uptake by the thymus were quite different from the changes in uptake by the marrow. The lowest thymic FDG uptake was found at cessation of chemotherapy. Thereafter, thymic activity steadily increased, reached a peak on average 10 months after therapy, and then slowly decreased.

Conclusion

Knowledge of the time-dependent changes in metabolic activity in the thymus and marrow is important to avoid misinterpretation of increased 18F-FDG uptake as disease in the off-therapy setting.
Literatur
1.
Zurück zum Zitat Cheson BD. Staging and evaluation of the patient with lymphoma. Hematol Oncol Clin North Am 2008;22:825–37.CrossRefPubMed Cheson BD. Staging and evaluation of the patient with lymphoma. Hematol Oncol Clin North Am 2008;22:825–37.CrossRefPubMed
2.
Zurück zum Zitat Terasawa T, Lau J, Bardet S, Couturier O, Hotta T, Hutchings M, et al. Fluorine-18-fluorodeoxyglucose positron emission tomography for interim response assessment of advanced-stage Hodgkin’s lymphoma and diffuse large B-cell lymphoma: a systematic review. J Clin Oncol 2009;27:1906–14.CrossRefPubMed Terasawa T, Lau J, Bardet S, Couturier O, Hotta T, Hutchings M, et al. Fluorine-18-fluorodeoxyglucose positron emission tomography for interim response assessment of advanced-stage Hodgkin’s lymphoma and diffuse large B-cell lymphoma: a systematic review. J Clin Oncol 2009;27:1906–14.CrossRefPubMed
3.
Zurück zum Zitat Iagaru A, Wang Y, Mari C, Quon A, Goris ML, Horning S, et al. (18)F-FDG-PET/CT evaluation of response to treatment in lymphoma: when is the optimal time for the first re-evaluation scan? Hell J Nucl Med 2008;11:153–6.PubMed Iagaru A, Wang Y, Mari C, Quon A, Goris ML, Horning S, et al. (18)F-FDG-PET/CT evaluation of response to treatment in lymphoma: when is the optimal time for the first re-evaluation scan? Hell J Nucl Med 2008;11:153–6.PubMed
4.
Zurück zum Zitat Kobe C, Dietlein M, Franklin J, Markova J, Lohri A, Amthauer H, et al. Positron emission tomography has a high negative predictive value for progression or early relapse for patients with residual disease after first-line chemotherapy in advanced-stage Hodgkin lymphoma. Blood 2008;112:3989–94.CrossRefPubMed Kobe C, Dietlein M, Franklin J, Markova J, Lohri A, Amthauer H, et al. Positron emission tomography has a high negative predictive value for progression or early relapse for patients with residual disease after first-line chemotherapy in advanced-stage Hodgkin lymphoma. Blood 2008;112:3989–94.CrossRefPubMed
5.
Zurück zum Zitat Schoder H, Moskowitz C. PET imaging for response assessment in lymphoma: potential and limitations. Radiol Clin North Am 2008;46:225–41.CrossRefPubMed Schoder H, Moskowitz C. PET imaging for response assessment in lymphoma: potential and limitations. Radiol Clin North Am 2008;46:225–41.CrossRefPubMed
6.
Zurück zum Zitat Abramson SJ, Price AP. Imaging of pediatric lymphomas. Radiol Clin North Am 2008;46:313–38.CrossRefPubMed Abramson SJ, Price AP. Imaging of pediatric lymphomas. Radiol Clin North Am 2008;46:313–38.CrossRefPubMed
7.
Zurück zum Zitat Allen-Auerbach M, de Vos S, Czernin J. The impact of fluorodeoxyglucose-positron emission tomography in primary staging and patient management in lymphoma patients. Radiol Clin North Am 2008;46:199–211.CrossRefPubMed Allen-Auerbach M, de Vos S, Czernin J. The impact of fluorodeoxyglucose-positron emission tomography in primary staging and patient management in lymphoma patients. Radiol Clin North Am 2008;46:199–211.CrossRefPubMed
8.
Zurück zum Zitat Ferdinand B, Gupta P, Kramer EL. Spectrum of thymic uptake at 18F-FDG PET. Radiographics 2004;24:1611–6.CrossRefPubMed Ferdinand B, Gupta P, Kramer EL. Spectrum of thymic uptake at 18F-FDG PET. Radiographics 2004;24:1611–6.CrossRefPubMed
9.
Zurück zum Zitat Patel PM, Alibazoglu H, Ali A, Fordham E, LaMonica G. Normal thymic uptake of FDG on PET imaging. Clin Nucl Med 1996;21:772–5.CrossRefPubMed Patel PM, Alibazoglu H, Ali A, Fordham E, LaMonica G. Normal thymic uptake of FDG on PET imaging. Clin Nucl Med 1996;21:772–5.CrossRefPubMed
10.
Zurück zum Zitat Nakahara T, Fujii H, Ide M, Nishiumi N, Takahashi W, Yasuda S, et al. FDG uptake in the morphologically normal thymus: comparison of FDG positron emission tomography and CT. Br J Radiol 2001;74:821–4.PubMed Nakahara T, Fujii H, Ide M, Nishiumi N, Takahashi W, Yasuda S, et al. FDG uptake in the morphologically normal thymus: comparison of FDG positron emission tomography and CT. Br J Radiol 2001;74:821–4.PubMed
11.
Zurück zum Zitat Elstrom RL, Tsai DE, Vergilio JA, Downs LH, Alavi A, Schuster SJ. Enhanced marrow [18F]fluorodeoxyglucose uptake related to myeloid hyperplasia in Hodgkin’s lymphoma can simulate lymphoma involvement in marrow. Clin Lymphoma 2004;5:62–4.CrossRefPubMed Elstrom RL, Tsai DE, Vergilio JA, Downs LH, Alavi A, Schuster SJ. Enhanced marrow [18F]fluorodeoxyglucose uptake related to myeloid hyperplasia in Hodgkin’s lymphoma can simulate lymphoma involvement in marrow. Clin Lymphoma 2004;5:62–4.CrossRefPubMed
12.
Zurück zum Zitat Lin EC. FDG PET/CT flip flop phenomenon in treated lymphoma of bone. Clin Nucl Med 2006;31:803–5.CrossRefPubMed Lin EC. FDG PET/CT flip flop phenomenon in treated lymphoma of bone. Clin Nucl Med 2006;31:803–5.CrossRefPubMed
13.
Zurück zum Zitat Kazama T, Swanston N, Podoloff DA, Macapinlac HA. Effect of colony-stimulating factor and conventional- or high-dose chemotherapy on FDG uptake in bone marrow. Eur J Nucl Med Mol Imaging 2005;32:1406–11.CrossRefPubMed Kazama T, Swanston N, Podoloff DA, Macapinlac HA. Effect of colony-stimulating factor and conventional- or high-dose chemotherapy on FDG uptake in bone marrow. Eur J Nucl Med Mol Imaging 2005;32:1406–11.CrossRefPubMed
14.
Zurück zum Zitat Sugawara Y, Fisher SJ, Zasadny KR, Kison PV, Baker LH, Wahl RL. Preclinical and clinical studies of bone marrow uptake of fluorine-1-fluorodeoxyglucose with or without granulocyte colony-stimulating factor during chemotherapy. J Clin Oncol 1998;16:173–80.PubMed Sugawara Y, Fisher SJ, Zasadny KR, Kison PV, Baker LH, Wahl RL. Preclinical and clinical studies of bone marrow uptake of fluorine-1-fluorodeoxyglucose with or without granulocyte colony-stimulating factor during chemotherapy. J Clin Oncol 1998;16:173–80.PubMed
15.
Zurück zum Zitat Yao WJ, Hoh CK, Hawkins RA, Glaspy JA, Weil JA, Lee SJ, et al. Quantitative PET imaging of bone marrow glucose metabolic response to hematopoietic cytokines. J Nucl Med 1995;36:794–9.PubMed Yao WJ, Hoh CK, Hawkins RA, Glaspy JA, Weil JA, Lee SJ, et al. Quantitative PET imaging of bone marrow glucose metabolic response to hematopoietic cytokines. J Nucl Med 1995;36:794–9.PubMed
16.
Zurück zum Zitat Knopp MV, Bischoff H, Rimac A, Oberdorfer F, van Kaick G. Bone marrow uptake of fluorine-18-fluorodeoxyglucose following treatment with hematopoietic growth factors: initial evaluation. Nucl Med Biol 1996;23:845–9.CrossRefPubMed Knopp MV, Bischoff H, Rimac A, Oberdorfer F, van Kaick G. Bone marrow uptake of fluorine-18-fluorodeoxyglucose following treatment with hematopoietic growth factors: initial evaluation. Nucl Med Biol 1996;23:845–9.CrossRefPubMed
17.
Zurück zum Zitat Kaste SC, Howard SC, McCarville EB, Krasin MJ, Kogos PG, Hudson MM. 18F-FDG-avid sites mimicking active disease in pediatric Hodgkin’s. Pediatr Radiol 2005;35:141–54.CrossRefPubMed Kaste SC, Howard SC, McCarville EB, Krasin MJ, Kogos PG, Hudson MM. 18F-FDG-avid sites mimicking active disease in pediatric Hodgkin’s. Pediatr Radiol 2005;35:141–54.CrossRefPubMed
18.
Zurück zum Zitat Brink I, Reinhardt MJ, Hoegerle S, Altehoefer C, Moser E, Nitzsche EU. Increased metabolic activity in the thymus gland studied with 18F-FDG PET: age dependency and frequency after chemotherapy. J Nucl Med 2001;42:591–5.PubMed Brink I, Reinhardt MJ, Hoegerle S, Altehoefer C, Moser E, Nitzsche EU. Increased metabolic activity in the thymus gland studied with 18F-FDG PET: age dependency and frequency after chemotherapy. J Nucl Med 2001;42:591–5.PubMed
19.
Zurück zum Zitat Kawano T, Suzuki A, Ishida A, Takahashi N, Lee J, Tayama Y, et al. The clinical relevance of thymic fluorodeoxyglucose uptake in pediatric patients after chemotherapy. Eur J Nucl Med Mol Imaging 2004;31:831–6.CrossRefPubMed Kawano T, Suzuki A, Ishida A, Takahashi N, Lee J, Tayama Y, et al. The clinical relevance of thymic fluorodeoxyglucose uptake in pediatric patients after chemotherapy. Eur J Nucl Med Mol Imaging 2004;31:831–6.CrossRefPubMed
20.
Zurück zum Zitat Daube-Witherspoon M, Matej S, Karp J, Lewitt R. Application of the row action maximum likelihood algorithm with spherical basis functions to clinical PET imaging. IEEE Trans Nucl Sci 2001;48:24–30.CrossRef Daube-Witherspoon M, Matej S, Karp J, Lewitt R. Application of the row action maximum likelihood algorithm with spherical basis functions to clinical PET imaging. IEEE Trans Nucl Sci 2001;48:24–30.CrossRef
22.
Zurück zum Zitat Hudson MM, Krasin MJ, Kaste SC. PET imaging in pediatric Hodgkin’s lymphoma. Pediatr Radiol 2004;34:190–8.CrossRefPubMed Hudson MM, Krasin MJ, Kaste SC. PET imaging in pediatric Hodgkin’s lymphoma. Pediatr Radiol 2004;34:190–8.CrossRefPubMed
23.
Zurück zum Zitat Smith CS, Schoder H, Yeung HW. Thymic extension in the superior mediastinum in patients with thymic hyperplasia: potential cause of false-positive findings on 18F-FDG PET/CT. AJR Am J Roentgenol 2007;188:1716–21.CrossRefPubMed Smith CS, Schoder H, Yeung HW. Thymic extension in the superior mediastinum in patients with thymic hyperplasia: potential cause of false-positive findings on 18F-FDG PET/CT. AJR Am J Roentgenol 2007;188:1716–21.CrossRefPubMed
24.
Zurück zum Zitat Pakos EE, Fotopoulos AD, Ioannidis JP. 18F-FDG PET for evaluation of bone marrow infiltration in staging of lymphoma: a meta-analysis. J Nucl Med 2005;46:958–63.PubMed Pakos EE, Fotopoulos AD, Ioannidis JP. 18F-FDG PET for evaluation of bone marrow infiltration in staging of lymphoma: a meta-analysis. J Nucl Med 2005;46:958–63.PubMed
25.
Zurück zum Zitat Gundlapalli S, Ojha B, Mountz JM. Granulocyte colony-stimulating factor: confounding F-18 FDG uptake in outpatient positron emission tomographic facilities for patients receiving ongoing treatment of lymphoma. Clin Nucl Med 2002;27:140–1.CrossRefPubMed Gundlapalli S, Ojha B, Mountz JM. Granulocyte colony-stimulating factor: confounding F-18 FDG uptake in outpatient positron emission tomographic facilities for patients receiving ongoing treatment of lymphoma. Clin Nucl Med 2002;27:140–1.CrossRefPubMed
26.
Zurück zum Zitat Corder MP, Jochimsen PR. Marrow neutrophil reserve after adjuvant chemotherapy for carcinoma of the breast. Cancer 1982;49:2455–8.CrossRefPubMed Corder MP, Jochimsen PR. Marrow neutrophil reserve after adjuvant chemotherapy for carcinoma of the breast. Cancer 1982;49:2455–8.CrossRefPubMed
27.
Zurück zum Zitat Gardner RV, Lerner C, Astle CM, Harrison DE. Assessing permanent damage to primitive hematopoietic stem cells after chemotherapy using the competitive repopulation assay. Cancer Chemother Pharmacol 1993;32:450–4.CrossRefPubMed Gardner RV, Lerner C, Astle CM, Harrison DE. Assessing permanent damage to primitive hematopoietic stem cells after chemotherapy using the competitive repopulation assay. Cancer Chemother Pharmacol 1993;32:450–4.CrossRefPubMed
Metadaten
Titel
Time-dependent changes in 18F-FDG activity in the thymus and bone marrow following combination chemotherapy in paediatric patients with lymphoma
verfasst von
Ingeborg Goethals
Pieter Hoste
Ciel De Vriendt
Peter Smeets
Joris Verlooy
Hamphrey Ham
Publikationsdatum
01.03.2010
Verlag
Springer-Verlag
Erschienen in
European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 3/2010
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-009-1280-0

Weitere Artikel der Ausgabe 3/2010

European Journal of Nuclear Medicine and Molecular Imaging 3/2010 Zur Ausgabe